Home>>Signaling Pathways>> Tyrosine Kinase>> TAM Receptor>>R428

R428 Sale

(Synonyms: R-428;R 428;BGB324) 目录号 : GC17618

R428作为一种Axl抑制剂,在纳摩尔浓度下阻断Axl在其C端对接位点Tyr821上的自动磷酸化。

R428 Chemical Structure

Cas No.:1037624-75-1

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥1,404.00
现货
1mg
¥585.00
现货
5mg
¥1,260.00
现货
10mg
¥2,250.00
现货
50mg
¥4,230.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

101

客户使用产品发表文献 1

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

B-CPAP cell line(derived from human PTC cancer tissue)

Preparation Method

The B-CPAP cell line was cultured and treated with the AXL inhibitor R428 at different concentrations (0.5 µmol/L, 1 µmol/L, 2 µmol/L, 4 µmol/L), and the untreated B-CPAP cell line was used as a control group. A CCK-8 assay was performed to assess the cell proliferation rate.

Reaction Conditions

0.5 µmol/L, 1 µmol/L, 2 µmol/L, 4 µmol/L; for 24 h

Applications

In the B-CPAP experimental group, the cell survival rates after treatment with 0.5, 1.0, 2.0, and 4.0 µmol/L R428 were 85.28% ± 9.21%, 66.74% ± 3.88%, 41.51% ± 6.33%, and 3.71% ± 2.10%, respectively.

Animal experiment [2]:

Animal models

NOD-SCID male mice

Preparation Method

In the animal model, ESCC (Esophageal squamous cell carcinoma) xenograft models were established by injecting KYSE-70 cells with Matrigel into the upper back region of NOD-SCID male mice followed by treatment with vehicle control, R428 (50 mg/kg/day), cisplatin (1.0 mg/kg), or cabozantinib (30 mg/kg/day) for the indicated number of days.

Dosage form

50 mg/kg/day; i.p.

Applications

R428 alone significantly inhibited ESCC tumor growth compared to the vehicle; however, no synergistic effect with cisplatin was observed.

References:

[1] Wei M, et al. AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour. World J Surg Oncol. 2022 Oct 6;20(1):334.
[2] Yang PW, et al. Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC). Front Oncol. 2019 Nov 6;9:1138.

产品描述

R428, as a Axl inhibitor, blocks Axl autophosphorylation on its C-terminal docking site, Tyr821, at nanomolar concentrations[1].

In vitro, R428 inhibited growth of H1299, a human non-small cell lung carcinoma cell line that had constitutively activated Axl, in a dose-dependent manner with an IC50 of approximately 4 µM[1]. In CE81T cells, the IC50 value of R428 was 1.98 µM when treated for 72 h[2]. In vitro, TNBC cells were treated with 0.5, 1 or 2 µM R428 for 30 min, 1-, 2- and 4-h disrupted the polarized localization of the Golgi apparatus towards the leading edge in migratory cells[3].

In vivo, rats were administrated 100 mg/kg body weight (p.o.) R428 that shown more severe RV hypertrophy, augmented right ventricular systolic pressure (RVSP), impaired cardiac output and worsened tricuspid annular plane systolic excursion, and a significantly increased total pulmonary vascular resistance index[4]. In vivo efficacy test it shown that R428 has a long plasma half-life (13 hours at 75 mg/kg), and distributes effectively to tissue[5].

In vivo, mice (8 weeks of age) were treated with 125 mg/kg R428 orally significantly reduced number of CD4+ T cells in the kidney compared to the T cell numbers in the kidney of nephritic B6 mice[6].

References:

[1] Chen F, et al. Axl inhibitor R428 induces apoptosis of cancer cells by blocking lysosomal acidification and recycling independent of Axl inhibition. Am J Cancer Res. 2018 Aug 1;8(8):1466-1482.

[2] Yang PW, et al. Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC). Front Oncol. 2019 Nov 6;9:1138.

[3] Zajac O, et al. AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells. Cells. 2020 Jan 19;9(1):247.

[4] Novoyatleva T, et al. Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. Commun Biol. 2021 Aug 24;4(1):1002. doi: 10.1038/s42003-021-02531-1. Erratum in: Commun Biol. 2022 Jan 20;5(1):97.

[5] Zhen Y, et al. Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis. J Autoimmun. 2018 Sep;93:37-44.

[6] Zhen Y, et al. Axl regulated survival/proliferation network and its therapeutic intervention in mouse models of glomerulonephritis. Arthritis Res Ther. 2022 Dec 28;24(1):284.

R428作为一种Axl抑制剂,在纳摩尔浓度下阻断Axl在其C端对接位点Tyr821上的自动磷酸化[1]。

在体外,R428以剂量依赖的方式抑制H1299的生长,H1299是一种人类非小细胞肺癌细胞系,它具有构成性激活的Axl,IC50约为4µM[1]。在CE81T细胞中,处理72小时时,R428的IC50值为1.98 µM[2]。在体外,用0.5、1或2 µM的R428处理TNBC细胞30分钟,1、2和4小时,破坏了迁移细胞中高尔基体向前缘的极化定位[3]。

在体内,大鼠服用100 mg/kg (p.o.)的R428,显示出更严重的RV肥大,右心室收缩压(RVSP)增加,心输出量受损,三尖瓣环面收缩期延长,总肺血管阻力指数明显增加[4]。体内药效试验表明,R428具有较长的血浆半衰期(75mg/kg时为13小时),并能有效地分布到组织中[5]。 在体内,小鼠(8周龄)用125mg/kg R428口服治疗,与肾炎B6小鼠肾脏中的T细胞数量相比,肾脏中的CD4+T细胞数量明显减少[6]。

Chemical Properties

Cas No. 1037624-75-1 SDF
别名 R-428;R 428;BGB324
化学名 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine
Canonical SMILES C1CCN(C1)C2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76
分子式 C30H34N8 分子量 506.64
溶解度 ≥ 25mg/mL in DMSO with gentle warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.9738 mL 9.8689 mL 19.7379 mL
5 mM 0.3948 mL 1.9738 mL 3.9476 mL
10 mM 0.1974 mL 0.9869 mL 1.9738 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置